Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis.

OBJECTIVE

Platelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT).

DESIGN

Meta-analysis.

DATA SOURCES

Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library.

ELIGIBILITY CRITERIA

All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included.

DATA EXTRACTION AND SYNTHESIS

Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters.

RESULTS

The last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p<0.001, I=75.80%, P<0.001) and poor prognosis, including overall survival (OS) (HR 1.90, 95% CI 1.39 to 2.59, p<0.001; I=7.40%, P=0.365) and disease-free survival (HR 1.97, 95% CI 1.56 to 2.50, p<0.001; I=0.0%, P=0.460). Furthermore, PLR level was associated with age (OR 0.86, 95% CI 0.79 to 0.93, p<0.001, I=40.60%, P=0.096), menopausal status (OR 0.83, 95% CI 0.76 to 0.90, p<0.001, I=50.80%, P=0.087) and T stage (OR 1.05, 95% CI 1.00 to 1.11, p=0.035; I=70.30%, P=0.005) of patients with BC.

CONCLUSIONS

This meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.